- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04964934
Fase III-studie for å vurdere AZD9833+ CDK4/6-hemmer i HR+/HER2-MBC med påvisbar ESR1m før progresjon (SERENA-6) (SERENA-6)
En fase III, dobbeltblind, randomisert studie for å vurdere bytte til AZD9833 (en neste generasjons, oral SERD) + CDK4/6-hemmer (Palbociclib eller Abemaciclib) vs kontinuerlig aromatasehemmer (letrozol eller anastrozol) + CDK4/6+/hemmer i HR HER2-MBC-pasienter med påvisbar ESR1-mutasjon uten sykdomsprogresjon under 1L-behandling med aromatasehemmer+ CDK4/6-hemmer- A ctDNA-veiledet studie med tidlig bytte
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.
This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.
The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.
Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:
- palbociclib + anastrozole
- palbociclib + letrozole
- abemaciclib + anastrozole
- abemaciclib + letrozole
- ribociclib + anastrozole
- ribociclib + letrozole
During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.
In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.
The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.
The researchers also want to know more about how safe AZD9833 is.
The trial participants will be split into 2 groups:
- Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
- Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo
A placebo looks like a treatment but does not have any medicine in it.
A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.
The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.
Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Birtinya, Australia, 4575
- Research Site
-
Darlinghurst, Australia, 2010
- Research Site
-
-
-
-
-
Leuven, Belgia, 3000
- Research Site
-
Liège, Belgia, 4000
- Research Site
-
Namur, Belgia, 5000
- Research Site
-
-
-
-
-
Haskovo, Bulgaria, 6300
- Research Site
-
Panagyurishte, Bulgaria, 4500
- Research Site
-
Pleven, Bulgaria, 5804
- Research Site
-
Plovdiv, Bulgaria, 4004
- Research Site
-
Sofia, Bulgaria, 1431
- Research Site
-
Sofia, Bulgaria, 1407
- Research Site
-
Sofia, Bulgaria, 1527
- Research Site
-
Sofia, Bulgaria, 1330
- Research Site
-
Sofia, Bulgaria, 1303
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Research Site
-
-
Quebec
-
Lévis, Quebec, Canada, G6V 3Z1
- Research Site
-
Montreal, Quebec, Canada, H2X 0C1
- Research Site
-
Montreal, Quebec, Canada, H3T 1E2
- Research Site
-
Montreal, Quebec, Canada, H1T 2M4
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Forente stater, 71913
- Research Site
-
Little Rock, Arkansas, Forente stater, 72205
- Research Site
-
-
California
-
Long Beach, California, Forente stater, 90806
- Research Site
-
San Diego, California, Forente stater, 92123
- Research Site
-
Santa Rosa, California, Forente stater, 92805
- Research Site
-
-
Colorado
-
Grand Junction, Colorado, Forente stater, 81501
- Research Site
-
Lone Tree, Colorado, Forente stater, 80124
- Research Site
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33901
- Research Site
-
Jacksonville, Florida, Forente stater, 32256
- Research Site
-
Jacksonville, Florida, Forente stater, 32224
- Research Site
-
St. Petersburg, Florida, Forente stater, 33705
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30318
- Research Site
-
Atlanta, Georgia, Forente stater, 30322
- Research Site
-
Atlanta, Georgia, Forente stater, 30342
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Forente stater, 60068
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Forente stater, 46804
- Research Site
-
Indianapolis, Indiana, Forente stater, 46250
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21202
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Research Site
-
Fairhaven, Massachusetts, Forente stater, 02719
- Research Site
-
Foxborough, Massachusetts, Forente stater, 02035
- Research Site
-
Milford, Massachusetts, Forente stater, 01757
- Research Site
-
South Weymouth, Massachusetts, Forente stater, 02190
- Research Site
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Research Site
-
Grand Rapids, Michigan, Forente stater, 49503
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Research Site
-
-
Mississippi
-
Oxford, Mississippi, Forente stater, 38655
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Research Site
-
St Louis, Missouri, Forente stater, 63110
- Research Site
-
-
Montana
-
Billings, Montana, Forente stater, 59101
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68130
- Research Site
-
-
New Jersey
-
Camden, New Jersey, Forente stater, 08103
- Research Site
-
Ridgewood, New Jersey, Forente stater, 07450
- Research Site
-
-
New York
-
Brooklyn, New York, Forente stater, 11215
- Research Site
-
East Syracuse, New York, Forente stater, 13057
- Research Site
-
New Hyde Park, New York, Forente stater, 11042
- Research Site
-
New York, New York, Forente stater, 10065
- Research Site
-
New York, New York, Forente stater, 11355
- Research Site
-
Shirley, New York, Forente stater, 11967
- Research Site
-
-
North Carolina
-
Goldsboro, North Carolina, Forente stater, 27534
- Research Site
-
-
Ohio
-
Canton, Ohio, Forente stater, 44710
- Research Site
-
Cincinnati, Ohio, Forente stater, 45220
- Research Site
-
Columbus, Ohio, Forente stater, 43219
- Research Site
-
-
Oregon
-
Portland, Oregon, Forente stater, 97213
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Research Site
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Research Site
-
York, Pennsylvania, Forente stater, 17403
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29607
- Research Site
-
West Columbia, South Carolina, Forente stater, 29169
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37916
- Research Site
-
Memphis, Tennessee, Forente stater, 38120
- Research Site
-
Nashville, Tennessee, Forente stater, 37203
- Research Site
-
-
Texas
-
Bedford, Texas, Forente stater, 76022
- Research Site
-
Dallas, Texas, Forente stater, 75246
- Research Site
-
Houston, Texas, Forente stater, 77030
- Research Site
-
Houston, Texas, Forente stater, 77024
- Research Site
-
Longview, Texas, Forente stater, 75601
- Research Site
-
San Antonio, Texas, Forente stater, 78240
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84106
- Research Site
-
-
Virginia
-
Midlothian, Virginia, Forente stater, 23114
- Research Site
-
Norfolk, Virginia, Forente stater, 23502
- Research Site
-
-
Washington
-
Tacoma, Washington, Forente stater, 98405
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Forente stater, 53226
- Research Site
-
-
-
-
-
Avignon, Frankrike, 84918
- Research Site
-
Brest, Frankrike, 29200
- Research Site
-
Clermont-Ferrand, Frankrike, 63050
- Research Site
-
Dijon, Frankrike, 21079
- Research Site
-
Limoges, Frankrike, 83000
- Research Site
-
Lorient, Frankrike, 56322
- Research Site
-
Lyon, Frankrike, 69373
- Research Site
-
Marseille, Frankrike, 13273
- Research Site
-
Metz-Tessy, Frankrike, 74370
- Research Site
-
Nîmes, Frankrike, 30029
- Research Site
-
Paris, Frankrike, 75248
- Research Site
-
Rouen, Frankrike, 76021
- Research Site
-
Saint-Cloud, Frankrike, 92210
- Research Site
-
Saint-Herblain, Frankrike, 44805
- Research Site
-
Toulouse, Frankrike, 31100
- Research Site
-
Tours, Frankrike, 37000
- Research Site
-
Vandœuvre-lès-Nancy, Frankrike, 54519
- Research Site
-
Vantoux, Frankrike, 57070
- Research Site
-
Villejuif, Frankrike, 94805
- Research Site
-
-
-
-
-
Beersheba, Israel, 8410101
- Research Site
-
Haifa, Israel, 3109601
- Research Site
-
Jerusalem, Israel, 91120
- Research Site
-
Petah Tikva, Israel, 494142
- Research Site
-
Ramat Gan, Israel, 5262000
- Research Site
-
-
-
-
-
Bergamo, Italia, 24127
- Research Site
-
Bologna, Italia, 40138
- Research Site
-
Florence, Italia, 50134
- Research Site
-
Meldola, Italia, 47014
- Research Site
-
Milan, Italia, 20141
- Research Site
-
Milan, Italia, 20132
- Research Site
-
Misterbianco, Italia, 95045
- Research Site
-
Naples, Italia, 80131
- Research Site
-
Padova, Italia, 35128
- Research Site
-
Roma, Italia, 00168
- Research Site
-
Rozzano, Italia, 20089
- Research Site
-
-
-
-
-
Chiba, Japan, 260-8717
- Research Site
-
Chūōku, Japan, 104-0045
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Research Site
-
Kumamoto, Japan, 860-8556
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Matsuyama, Japan, 791-0280
- Research Site
-
Nagoya, Japan, 464-8681
- Research Site
-
Nagoya, Japan, 467-8602
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Osaka, Japan, 540-0006
- Research Site
-
Osaka, Japan, 541-8567
- Research Site
-
Ota-shi, Japan, 373-8550
- Research Site
-
Sapporo, Japan, 003-0804
- Research Site
-
Shinagawa-ku, Japan, 142-8666
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Research Site
-
Takasaki-shi, Japan, 370-0829
- Research Site
-
Takatsuki-shi, Japan, 569-8686
- Research Site
-
Tsukuba, Japan, 305-8577
- Research Site
-
Yokohama, Japan, 241-8515
- Research Site
-
-
-
-
-
Drammen, Norge, 3004
- Research Site
-
Oslo, Norge, 0450
- Research Site
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Research Site
-
Gdynia, Polen, 81-519
- Research Site
-
Koszalin, Polen, 75-581
- Research Site
-
Lodz, Polen, 90-302
- Research Site
-
Poznan, Polen, 60-693
- Research Site
-
Rzeszów, Polen, 35-001
- Research Site
-
Tomaszów Mazowiecki, Polen, 97-200
- Research Site
-
Warsaw, Polen, 02-781
- Research Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Lisbon, Portugal, 1500-650
- Research Site
-
Lisbon, Portugal, 1449-005
- Research Site
-
Loures, Portugal, 2674-514
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
Porto, Portugal, 4200-319
- Research Site
-
Porto, Portugal, 4200-072
- Research Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Research Site
-
-
-
-
-
Moscow, Russland, 111123
- Research Site
-
Moscow, Russland, 143423
- Research Site
-
Moscow, Russland, 129090
- Research Site
-
Nizhny Novgorod, Russland, 603126
- Research Site
-
Podolsk, Russland, 142100
- Research Site
-
Saint Petersburg, Russland, 197758
- Research Site
-
Saint Petersburg, Russland, 194017
- Research Site
-
-
-
-
-
Banská Bystrica, Slovakia, 974 01
- Research Site
-
Bratislava, Slovakia, 833 01
- Research Site
-
Košice, Slovakia, 041 91
- Research Site
-
Michalovce, Slovakia, 07101
- Research Site
-
Partizánske, Slovakia, 958 01
- Research Site
-
-
-
-
-
A Coruña, Spania, 15009
- Research Site
-
Badalona, Spania, 08003
- Research Site
-
Barcelona, Spania, 8035
- Research Site
-
L'Hospitalet de Llobregat, Spania, 08908
- Research Site
-
Madrid, Spania, 28041
- Research Site
-
Madrid, Spania, 28040
- Research Site
-
Murcia, Spania, 30008
- Research Site
-
Málaga, Spania, 29010
- Research Site
-
Sant Joan Despí, Spania, 08970
- Research Site
-
Seville, Spania, 41013
- Research Site
-
Valencia, Spania, 46010
- Research Site
-
-
-
-
-
Blackpool, Storbritannia, FY3 8NR
- Research Site
-
Cambridge, Storbritannia, CB2 0QQ
- Research Site
-
London, Storbritannia, SW3 6JJ
- Research Site
-
London, Storbritannia, WC1N 3BG
- Research Site
-
Manchester, Storbritannia, M20 4BX
- Research Site
-
Newport, Storbritannia, NP10 8FZ
- Research Site
-
Nottingham, Storbritannia, NG5 1PB
- Research Site
-
Portsmouth, Storbritannia, PO6 3LY
- Research Site
-
Reading, Storbritannia, RG2 9LH
- Research Site
-
Sheffield, Storbritannia, S10 2SJ
- Research Site
-
Sutton, Storbritannia, SM2 5PT
- Research Site
-
Taunton, Storbritannia, TA1 5DA
- Research Site
-
-
-
-
-
Bern, Sveits, CH-3010
- Research Site
-
Chur, Sveits, CH-7000
- Research Site
-
Winterthur, Sveits, 8401
- Research Site
-
-
-
-
-
Cheonan-si, Sør -Korea, 31151
- Research Site
-
Daegu, Sør -Korea, 42415
- Research Site
-
Goyang-si, Sør -Korea, 10408
- Research Site
-
Seongnam-si, Sør -Korea, 13620
- Research Site
-
Seongnam-si, Sør -Korea, 463-712
- Research Site
-
Seoul, Sør -Korea, 02841
- Research Site
-
Seoul, Sør -Korea, 03080
- Research Site
-
Seoul, Sør -Korea, 03722
- Research Site
-
Seoul, Sør -Korea, 05505
- Research Site
-
Seoul, Sør -Korea, 06273
- Research Site
-
Seoul, Sør -Korea, 06351
- Research Site
-
Seoul, Sør -Korea, 06591
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Research Site
-
Taichung, Taiwan, 40705
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Tainan, Taiwan, 710
- Research Site
-
Taipei, Taiwan, 100
- Research Site
-
Taipei, Taiwan
- Research Site
-
Taipei, Taiwan, 11490
- Research Site
-
Taipei, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 11259
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Adana, Tyrkia (Türkiye), 01120
- Research Site
-
Ankara, Tyrkia (Türkiye), 06100
- Research Site
-
Ankara, Tyrkia (Türkiye), 06520
- Research Site
-
Ankara, Tyrkia (Türkiye), 06010
- Research Site
-
Ankara, Tyrkia (Türkiye), 06340
- Research Site
-
Cordaleo, Tyrkia (Türkiye), 35575
- Research Site
-
Izmir, Tyrkia (Türkiye), 35100
- Research Site
-
Izmir, Tyrkia (Türkiye), 35360
- Research Site
-
Kadıkoy/Istanbul, Tyrkia (Türkiye), 34722
- Research Site
-
Kayseri, Tyrkia (Türkiye), 38039
- Research Site
-
-
-
-
-
Ansbach, Tyskland, 91522
- Research Site
-
Augsburg, Tyskland, 86156
- Research Site
-
Bonn, Tyskland, 53111
- Research Site
-
Chemnitz, Tyskland, 09116
- Research Site
-
Dresden, Tyskland, 01307
- Research Site
-
Erlangen, Tyskland, 91054
- Research Site
-
Essen, Tyskland, 45130
- Research Site
-
Freiburg im Breisgau, Tyskland, 79110
- Research Site
-
Hösbach, Tyskland, 63768
- Research Site
-
Immenstadt im Allgäu, Tyskland, 87509
- Research Site
-
Koblenz, Tyskland, 56068
- Research Site
-
Leipzig, Tyskland, 4103
- Research Site
-
Mannheim, Tyskland, 68167
- Research Site
-
München, Tyskland, 80634
- Research Site
-
Paderborn, Tyskland, 33098
- Research Site
-
Ratingen, Tyskland, 40878
- Research Site
-
Ravensburg, Tyskland, 88212
- Research Site
-
Regensburg, Tyskland, 93053
- Research Site
-
Stade, Tyskland, 21680
- Research Site
-
Tübingen, Tyskland, 72076
- Research Site
-
Ulm, Tyskland, 89075
- Research Site
-
-
-
-
-
Budapest, Ungarn, 1122
- Research Site
-
Budapest, Ungarn, 1062
- Research Site
-
Miskolc, Ungarn, 3526
- Research Site
-
Szekszárd, Ungarn, 7100
- Research Site
-
Szolnok, Ungarn, 5000
- Research Site
-
Zalaegerszeg, Ungarn, 8900
- Research Site
-
-
-
-
-
Graz, Østerrike, 8036
- Research Site
-
Innsbruck, Østerrike, 6020
- Research Site
-
Salzburg, Østerrike, 5020
- Research Site
-
Vienna, Østerrike, 1130
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
INCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:
- Have advanced breast cancer that is not able to be treated with surgery or radiation;
- Have an ESR1 mutation in their cancer;
- Have breast cancer that is HR-positive and HER2-negative;
- Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
- Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
- Are able to do their daily activities;
- Are at least 18.
Full list of inclusion criteria:
- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
- Eastern Cooperative Oncology Group performance status of 0 or 1;
- ESR1m detected by central testing of ctDNA with Guardant360® CDx;
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
- Adequate organ and marrow function.
EXCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:
- Had certain types of tumors in the past that may come back;
- Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
- Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
Full list of exclusion criteria:
- Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
- Patient with known or family history of severe heart disease;
- Previous treatment with AZD9833, investigational SERDs or fulvestrant;
- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: AZD9833 + palbociclib, abemaciclib or ribociclib
The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily) |
Dosage formulation: AZD9833 tablets will be administered orally Dosage formulation: anastrozole placebo tablets will be administrated orally. Dosage formulation: letrozole placebo tablets will be administered orally. Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally |
|
Aktiv komparator: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib
The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily) |
Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally Dosage formulation: AZD9833 placebo tablets will be administrated orally. Dosage formulation: anastrozole tablets will be administered orally. Dosage formulation: letrozole tablets will be administered orally. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Tidsramme: From randomization until the earlier of the progression event or death (approximately 2 years)
|
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death. |
From randomization until the earlier of the progression event or death (approximately 2 years)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival 2 (PFS2)
Tidsramme: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death. |
From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
|
Overall survival (OS)
Tidsramme: From randomization until the date of death due to any cause (approximately 5 years)
|
The OS is defined as the time from randomization to death due to any cause. |
From randomization until the date of death due to any cause (approximately 5 years)
|
|
Chemotherapy free survival
Tidsramme: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause. |
From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
|
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Tidsramme: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1. |
From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
|
Clinical benefit rate at 24 weeks (CBR24)
Tidsramme: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment) |
At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
|
Change from baseline in EORTC QLQ-C30 scale scores
Tidsramme: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Change from baseline in EORTC QLQ-BR23 scale scores
Tidsramme: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Plasma concentration of AZD9833 at specified timepoints
Tidsramme: on Day 15 for each patient
|
To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration. |
on Day 15 for each patient
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1.
- Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
- Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, Bianchini G, Iwata H, Fasching PA, Nowecki Z, Pascual J, Chen SC, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Jung KH, Kikawa Y, Baird RD, Habash R, Sugarman R, Fox S, Selvi Miralles M, Huang Bartlett C, Turner N. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. Oncologist. 2026 Aug 6;31(9):oyag278. doi: 10.1093/oncolo/oyag278.
- Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13.
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Neoplasmer
- Dobbelblind
- Fase III
- Metastatisk
- Ribociclib
- Antineoplastiske midler
- Brystneoplasmer
- Fysiologiske effekter av legemidler
- Randomisert
- Endokrin terapi
- Letrozol
- Palbociclib
- Neoplasmer etter nettsted
- Bryst sykdommer
- Abemaciclib
- Anastrozol
- Multisenter
- AZD9833
- Neste generasjons oral SERD
- Antagonister
- Østrogenreseptorantagonister
- Hormonantagonister
- camizestrant
- ESR1m
- Bryterbehandling
- Endokrin motstand
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplastiske prosesser
- Hudsykdommer
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Neoplasmer
- Brystneoplasmer
- Neoplasma Metastase
- Bryst sykdommer
- Neoplasmer etter nettsted
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Humofyshormonfrigjørende hormoner
- Hypotalamiske hormoner
- Peptidhormoner
- Nevropeptider
- Peptider
- Aminosyrer, peptider og proteiner
- Oligopeptider
- Nervevevsproteiner
- Proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Nitriles
- Triazoler
- Letrozol
- Anastrozol
- Gonadotropinfrigjørende hormon
- Abemaciclib
- ribociclib
- palbociclib
- AZD9833
Andre studie-ID-numre
- D8534C00001
- 2023-503990-39-00 (Annen identifikator: EU CT number)
- 2021-000546-17 (EudraCT-nummer)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tilgangskriterier for IPD-deling
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .